ArticleHuman genomics2026
Integrating genomic and exposomic data identifies endocrine disruptors potentially associated with chronic obstructive pulmonary disease.
Article in Human genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundChronic obstructive pulmonary disease (COPD) is a complex disorder driven by both genetic susceptibility and environmental exposures. Endocrine-disrupting chemicals (EDCs) are widespread environmental contaminants that interfere with hormonal and immune pathways, yet their molecular links to COPD remain insufficiently defined.
methodsWe integrated exposomic and genomic data to systematically evaluate EDC-related molecular mechanisms in COPD. Chemical-gene interactions were curated from the TEDX and CTD to identify EDC-associated genes. Two-sample Mendelian randomization (MR) was performed to assess genetically supported associations between gene expression and COPD risk. Bayesian colocalization analysis was applied to determine whether shared genetic variants underlie both gene expression and COPD susceptibility. Network analyses were conducted to map EDC-gene interactions and protein-protein interaction (PPI) landscapes.
resultsAmong 4207 EDC-associated genes with available cis-eQTLs, MR identified 30 genes significantly associated with COPD after FDR correction. Colocalization analysis prioritized 18 genes with strong or moderate evidence of a shared genetic signal, including TCF19, MAP1LC3B, and IRF1. Network analyses revealed extensive interactions between these genes and multiple EDCs, such as bisphenol A, triclosan, and formaldehyde. Functional connectivity highlighted pathways related to immune regulation, autophagy, and epigenetic control.
conclusionThis integrative translational exposomics framework identifies genetically supported links between EDC-related genes and COPD risk. The findings provide mechanistic insights into how environmental endocrine disruptors may contribute to COPD pathogenesis and offer prioritized molecular targets for future experimental validation and environmental health interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.